TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (TCRX)

Q: What does CUSIP 89854M101 represent in this 13F holders report?

CUSIP 89854M101 is the security identifier for TCRX - TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share used to aggregate holder disclosures.

Q: How many institutions held TCRX - TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share in Q4 2025?

59 institutional investors reported TCRX - TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share for Q4 2025. Use the holders table for investor-level position and value details.

CUSIP: 89854M101

Q4 2025 13F Holders as of 31 Dec 2025

Type / Class: Equity / Voting Common Stock, par value $0.0001 per share
Shares outstanding: 52,382,313
Total 13F shares: 30,693,293
Share change: -3,847,451
Total reported value: $30,691,617
Price per share: $1.00
Number of holders: 59
Value change: -$7,374,797
Number of buys: 27
Number of sells: 38

Quarterly Holders Quick Answers

What is CUSIP 89854M101?
CUSIP 89854M101 identifies TCRX - TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q1 2026
Previous quarter: Q3 2025

Recent filing periods for CUSIP 89854M101:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of TCRX - TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Lynx1 Capital Management LP	3/4/5 13D/G 13F	10%+ Owner · Company	15% from 13D/G	15,519,148 mixed-class rows	$37,208,412	+$3,252,079	19 Dec 2025	3/4/5 13D/G 13F
EcoR1 Capital, LLC	3/4/5 13D/G	10%+ Owner	1.3% from 13D/G	5,000,000	$24,842,500	—	26 May 2023	3/4/5 13D/G
Christoph H. Westphal	3/4/5	10%+ Owner	— class O/S missing	2,193,472	$10,898,266	—	20 Jul 2021	3/4/5
BVF INC/IL	13F	Company	10%	5,226,074	$9,511,455	—	30 Sep 2025	13F
BIOTECHNOLOGY VALUE FUND L P	13D/G	BVF PARTNERS L P/IL	10%	5,263,541	$8,421,666	$0	31 Mar 2025	13D/G
K2 HealthVentures Equity Trust LLC	13D/G	—	6.9%	3,602,700	$5,764,320	$0	31 Dec 2024	13D/G
ADAGE CAPITAL PARTNERS GP, L.L.C.	13D/G	Adage Capital Management, L.P.	7.1%	3,500,000	$5,600,000	$0	31 Dec 2024	13D/G
BAKER BROS. ADVISORS LP	13F 3/4/5	Company · Director	5.3%	2,784,792	$5,068,321	—	30 Sep 2025	13F 3/4/5
BlackRock, Inc.	13F 13D/G	Company	1.8% from 13D/G	2,382,764	$4,336,629	—	30 Sep 2025	13F 13D/G
VANGUARD GROUP INC	13F	Company	4.4%	2,317,916	$4,218,607	—	30 Sep 2025	13F
Propel Bio Management, LLC	13F	Company	3.7%	1,932,304	$3,516,793	—	30 Sep 2025	13F
Aberdeen Group plc	13F	Company	2.6%	1,354,820	$2,465,772	—	30 Sep 2025	13F
Deer Management Co. LLC	13F	Company	2.4%	1,245,504	$2,266,817	—	30 Sep 2025	13F
Alphabet Inc.	13F	Company	2.1%	1,077,080	$1,960,286	—	30 Sep 2025	13F
Adage Capital Management, L.P.	13D/G	—	2.5%	1,350,000	$1,957,500	$0	30 Jun 2025	13D/G
Simplify Asset Management Inc.	13F	Company	1.7%	904,972	$1,647,049	—	30 Sep 2025	13F
MORGAN STANLEY	13F	Company	1.6%	847,537	$1,542,518	—	30 Sep 2025	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	1.6%	829,919	$1,510,453	—	30 Sep 2025	13F
DC Funds, LP	13F	Company	1.2%	630,000	$1,146,600	—	30 Sep 2025	13F
TANG CAPITAL MANAGEMENT LLC	13F	Company	1.1%	600,000	$1,092,000	—	30 Sep 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	1.1%	567,657	$1,033,532	—	30 Sep 2025	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.89%	466,086	$848,277	—	30 Sep 2025	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.8%	419,404	$763,315	—	30 Sep 2025	13F
CITADEL ADVISORS LLC	13F	Company	0.75%	390,747	$711,160	—	30 Sep 2025	13F
TWO SIGMA ADVISERS, LP	13F	Company	0.55%	288,800	$525,616	—	30 Sep 2025	13F
Timothy J. Barberich	3/4/5	Director	— mixed-class rows	135,286 mixed-class rows	$498,271	—	18 Dec 2023	3/4/5
JPMORGAN CHASE & CO	13F	Company	0.45%	237,750	$432,705	—	30 Sep 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.43%	223,024	$405,903	—	30 Sep 2025	13F
Barbara Klencke	3/4/5	Director	— mixed-class rows	137,000 mixed-class rows	$370,300	—	30 Jun 2025	3/4/5
STATE STREET CORP	13F	Company	0.38%	197,313	$359,110	—	30 Sep 2025	13F
BROWN BROTHERS HARRIMAN & CO	13F	Company	0.27%	143,051	$260,353	—	30 Sep 2025	13F
BRIDGEWAY CAPITAL MANAGEMENT, LLC	13F	Company	0.27%	140,400	$255,528	—	30 Sep 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.25%	130,980	$238,383	—	30 Sep 2025	13F
Militia Capital Partners, LP	13F	Company	0.19%	102,100	$185,822	—	30 Sep 2025	13F
NORTHERN TRUST CORP	13F	Company	0.19%	98,548	$179,357	—	30 Sep 2025	13F
STIFEL FINANCIAL CORP	13F	Company	0.19%	97,400	$177,268	—	30 Sep 2025	13F
LETKO, BROSSEAU & ASSOCIATES INC	13F	Company	0.18%	95,875	$174,493	—	30 Sep 2025	13F
DIMENSIONAL FUND ADVISORS LP	13F	Company	0.17%	87,316	$158,718	—	30 Sep 2025	13F
JANE STREET GROUP, LLC	13F	Company	0.16%	81,316	$147,995	—	30 Sep 2025	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.15%	79,760	$145,163	—	30 Sep 2025	13F
Virtu Financial LLC	13F	Company	0.12%	60,480	$110,000	—	30 Sep 2025	13F
NewEdge Wealth, LLC	13F	Company	0.17%	91,463	$103,811	—	30 Sep 2025	13F
Quadrature Capital Ltd	13F	Company	0.11%	56,666	$103,415	—	30 Sep 2025	13F
Voleon Capital Management LP	13F	Company	0.09%	47,879	$87,140	—	30 Sep 2025	13F
MARSHALL WACE, LLP	13F	Company	0.09%	46,630	$84,867	—	30 Sep 2025	13F
Cubist Systematic Strategies, LLC	13F	Company	0.08%	42,078	$76,582	—	30 Sep 2025	13F
DC Investments Management, LLC	13F	Company	0.07%	35,563	$64,725	—	30 Sep 2025	13F
Catalyst Funds Management Pty Ltd	13F	Company	0.06%	30,763	$55,989	—	30 Sep 2025	13F
BNP PARIBAS FINANCIAL MARKETS	13F	Company	0.06%	29,870	$54,363	—	30 Sep 2025	13F
ALGERT GLOBAL LLC	13F	Company	0.05%	28,030	$51,000	—	30 Sep 2025	13F

Institutional Holders of TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (TCRX) as of Q4 2025

As of 31 Dec 2025, TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (TCRX) was held by 59 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 30,693,293 shares. The largest 10 holders included Lynx1 Capital Management LP, BVF INC/IL, BAKER BROS. ADVISORS LP, VANGUARD GROUP INC, BlackRock, Inc., Aberdeen Group plc, Deer Management Co. LLC, RENAISSANCE TECHNOLOGIES LLC, TWO SIGMA INVESTMENTS, LP, and DC Funds, LP. This page lists 59 institutional shareholders reporting positions in this security for the Q4 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q4 2025 vs Q3 2025 Across Filers

Q3 2025 holders

Q4 2025 holders

Holder diff

-13

Investor	Q3 2025 Shares	Q4 2025 Shares	Share Diff	Share Chg %	Q3 2025 Value $	Q4 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.